Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025
Aethlon Medical (Nasdaq: AEMD), a medical therapeutic company developing products for cancer and infectious diseases treatment, has scheduled its fiscal third quarter financial results release for February 12, 2025, at 4:15 p.m. ET.
The company will host a conference call at 4:30 p.m. ET on the same day, featuring management's formal remarks followed by a Q&A session. The call will be accessible through pre-registration or direct dial-in, with replay available until March 12, 2025.
Aethlon Medical (Nasdaq: AEMD), un'azienda terapeutica medica che sviluppa prodotti per il trattamento del cancro e delle malattie infettive, ha programmato la pubblicazione dei risultati finanziari del terzo trimestre fiscale per il 12 febbraio 2025, alle 16:15 ET.
L'azienda ospiterà una conference call alle 16:30 ET dello stesso giorno, con un intervento formale della direzione seguito da una sessione di domande e risposte. La chiamata sarà accessibile tramite preregistrazione o accesso diretto, con registrazione disponibile fino al 12 marzo 2025.
Aethlon Medical (Nasdaq: AEMD), una empresa terapéutica médica que desarrolla productos para el tratamiento del cáncer y enfermedades infecciosas, ha programado la publicación de sus resultados financieros del tercer trimestre fiscal para el 12 de febrero de 2025, a las 4:15 p.m. ET.
La empresa llevará a cabo una conferencia telefónica a las 4:30 p.m. ET el mismo día, con comentarios formales de la dirección seguidos de una sesión de preguntas y respuestas. La llamada será accesible a través de preinscripción o marcando directamente, con una grabación disponible hasta el 12 de marzo de 2025.
Aethlon Medical (Nasdaq: AEMD), 암 및 감염병 치료 제품을 개발하는 의료 전문 기업,은 2025년 2월 12일 오후 4시 15분 ET에 회계 연도 3분기 재무 결과 발표를 예정하고 있습니다.
동일한 날 오후 4시 30분 ET에 경영진의 공식 발표와 이어지는 질의응답 세션을 포함한 컨퍼런스 콜을 주최할 예정입니다. 이 콜은 사전 등록 또는 직접 전화 접속을 통해 접근 가능하며, 2025년 3월 12일까지 재생 가능할 것입니다.
Aethlon Medical (Nasdaq: AEMD), une entreprise thérapeutique médicale développant des produits pour le traitement du cancer et des maladies infectieuses, a prévu la publication de ses résultats financiers pour le troisième trimestre fiscal le 12 février 2025 à 16h15 ET.
L'entreprise organisera une conférence téléphonique le même jour à 16h30 ET, comprenant des remarques formelles de la direction suivies d'une séance de questions-réponses. L'appel sera accessible par pré-inscription ou par appel direct, avec une rediffusion disponible jusqu'au 12 mars 2025.
Aethlon Medical (Nasdaq: AEMD), ein medizinisches Therapieunternehmen, das Produkte zur Behandlung von Krebs und Infektionskrankheiten entwickelt, hat die Veröffentlichung seiner finanziellen Ergebnisse für das dritte Quartal des Geschäftsjahres auf den 12. Februar 2025 um 16:15 Uhr ET angesetzt.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, bei der die formellen Anmerkungen des Managements gefolgt von einer Frage- und Antwortrunde präsentiert werden. Der Anruf ist über eine Voranmeldung oder direkte Einwahl zugänglich, mit einer Wiederholung, die bis zum 12. März 2025 verfügbar ist.
- None.
- None.
Management will host a conference call on Wednesday, February 12, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.
Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10196811/fe7c419c9d. Please note that registered participants will receive their dial-in number upon registration.
Interested parties without internet access or unable to pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the Aethlon Medical, Inc. conference call.
A replay of the call will be available approximately one hour after the end of the call through March 12, 2025. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a
Additional information can be found at www.AethlonMedical.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-fiscal-third-quarter-financial-results-and-host-conference-call-on-february-12-2025-302368735.html
SOURCE Aethlon Medical, Inc.
FAQ
When will Aethlon Medical (AEMD) release its Q3 2024 financial results?
How can investors join AEMD's Q3 2024 earnings conference call?
Until when will AEMD's Q3 2024 earnings call replay be available?
What is the replay conference ID for AEMD's Q3 2024 earnings call?
